All In Biotech

Drug Trial Radar · NCT01058018

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease

Last checked: Nov 19, 2026Latest source record: Apr 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 299 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

299

Actual

Start

Dec 2009

Primary completion

Jun 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
First posted
Jan 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate dose range, safety and efficacy of RVX000222 in subjects with stable coronary artery disease.

Conditions

  • Atherosclerosis
  • Coronary Artery Disease

Interventions

  • RVX000222Drug

    RVX000222 twice a day for 12 weeks

  • PlaceboDrug

    Placebo twice a day for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percent change in ApoA1 from baseline to 12 weeks post-randomization for each treatment arm compared to placebo.Time frame: from baseline to 12 weeks post-study drug treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Center

    Tustin, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.